HOME > COMMENTARY

COMMENTARY

Further Provisions Required – One Year since the Great East Japan Earthquake

March 12, 2012
Major US, European Drug Makers Report Growth in 2011 as Patent Cliff Approaches

March 5, 2012
Will Wholesalers Be Able to Succeed at Reform This Time?

February 20, 2012
Industry Should Prepare Arguments in Advance to Ward Off Possibility of 3 Consecutive NHI Price Revisions

January 23, 2012
Will New Drug Makers Dominate Domestic Biosimilars Market?

December 26, 2011
Pressure Mounting for Additional NHI Price Cut for Long-listed Drugs

December 12, 2011
“Drug Discovery Support Organization” Faces Doubts: Can It Pick Winners?

November 28, 2011
Perpetuation of Premium for New Drug Development Faces Hurdles

November 14, 2011
Further Research Needed to Advance the Use of Regulatory Science in Regulatory Affairs

November 14, 2011
Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations

October 19, 2011
Pinning Hope on Academia in Seeking a Radical Cure for AD

October 10, 2011
New Ideas Needed to Address “Insurance Lag” for GE Drug Makers That Submit Applications Based on Info. in Public Domain

October 3, 2011
Discussions on Amendment of PAL Now in Final Stages

October 3, 2011
Korosho Revises GL for Drafting, Distributing Drug Safety Information

September 5, 2011
Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public

August 29, 2011
Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate

August 8, 2011
Current Promising Drug Candidates with a New Mode of Action

August 8, 2011
Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System

July 18, 2011
Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan

July 4, 2011
Era of Competition Dawns in Market for AD Treatments

June 27, 2011

ページ

Upside in Decelerating Gx Arena

Meiji Pharma Pursuing Low-Cost Strategy to Weather Storm in Generics Space, Overseas Plants Hold Key

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

My Viewpoint on CEA

Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established

The Japanese cost-effectiveness assessment (CEA) scheme should be applied not only to the price adjustments of drugs and medical devices…

HTA Debates in 2018-2019

Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

TRENDS

Drug Makers on Hunt for “Mibyo” Biz Opportunities as Pricing Rules Get Stricter

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…

COMMENTARY

Generic Makers Shifting to Focus on “Specialty Area” Faced with Tougher Business Environment

By Tatsuya Otsuka

Driven by changes surrounding the Japanese generic drug market, generic companies are trying to shift from a “generic” to a “specialty” model for their main business, with more and more players steering their focus towards specialized areas to secure profits.The…

COLUMN

6 Core Elements of Recruitment Mastery

By Philip Carrigan

Watching a master craftsman at work is a sight to behold.With confidence forged over years of practice, complicated steps appear effortless, problems are smoothly managed, and the final product is perfect, in every sense of the word. Within each of…